UA68332C2 - Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants) - Google Patents
Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants) Download PDFInfo
- Publication number
- UA68332C2 UA68332C2 UA98126370A UA98126370A UA68332C2 UA 68332 C2 UA68332 C2 UA 68332C2 UA 98126370 A UA98126370 A UA 98126370A UA 98126370 A UA98126370 A UA 98126370A UA 68332 C2 UA68332 C2 UA 68332C2
- Authority
- UA
- Ukraine
- Prior art keywords
- polypeptide
- omp106
- sequence
- catarrhalis
- variants
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 390
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 371
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 368
- 238000000034 method Methods 0.000 title claims abstract description 65
- 229960005486 vaccine Drugs 0.000 title claims abstract description 29
- 241001465754 Metazoa Species 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000028993 immune response Effects 0.000 title claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 title claims description 25
- 102000007079 Peptide Fragments Human genes 0.000 title claims description 12
- 108010033276 Peptide Fragments Proteins 0.000 title claims description 12
- 230000002265 prevention Effects 0.000 title claims description 7
- 230000000890 antigenic effect Effects 0.000 title claims description 5
- 239000012528 membrane Substances 0.000 title abstract description 49
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract description 16
- 230000001939 inductive effect Effects 0.000 title abstract description 7
- 241000588655 Moraxella catarrhalis Species 0.000 title abstract 4
- 230000027455 binding Effects 0.000 title description 16
- 239000012634 fragment Substances 0.000 claims description 26
- 230000003053 immunization Effects 0.000 claims description 13
- 238000002649 immunization Methods 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000012876 topography Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 27
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000000069 prophylactic effect Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 105
- 108090000623 proteins and genes Proteins 0.000 description 63
- 230000003067 hemagglutinative effect Effects 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 49
- 230000035931 haemagglutination Effects 0.000 description 47
- 210000004379 membrane Anatomy 0.000 description 47
- 101710116435 Outer membrane protein Proteins 0.000 description 41
- 239000000284 extract Substances 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 40
- 239000000523 sample Substances 0.000 description 36
- 239000000499 gel Substances 0.000 description 34
- 239000013598 vector Substances 0.000 description 30
- 108091005804 Peptidases Proteins 0.000 description 22
- 102000035195 Peptidases Human genes 0.000 description 22
- 239000004365 Protease Substances 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- 238000002955 isolation Methods 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 229920002401 polyacrylamide Polymers 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 13
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000001962 electrophoresis Methods 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229930186217 Glycolipid Natural products 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 235000019419 proteases Nutrition 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 229910052709 silver Inorganic materials 0.000 description 9
- 239000004332 silver Substances 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 208000002109 Argyria Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 229940016590 sarkosyl Drugs 0.000 description 6
- 108700004121 sarkosyl Proteins 0.000 description 6
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100027573 ATP synthase subunit alpha, mitochondrial Human genes 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 101000936262 Homo sapiens ATP synthase subunit alpha, mitochondrial Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 102000003505 Myosin Human genes 0.000 description 4
- 108060008487 Myosin Proteins 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010073135 Phosphorylases Proteins 0.000 description 3
- 102000009097 Phosphorylases Human genes 0.000 description 3
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000003300 oropharynx Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 241000700626 Cowpox virus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- -1 and 6-8 of them Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000029586 bacterial cell surface binding Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000021309 simple sugar Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 1
- YBLJYSTXRAWBBH-PZRMXXKTSA-N (2s,3r,4s,5r,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YBLJYSTXRAWBBH-PZRMXXKTSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 1
- 241000218642 Abies Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710133359 Agglutinin receptor Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000408923 Appia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010037833 Bacterial Adhesins Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical class NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 108010008385 glycolipid receptor Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013376 serial cultivation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/642,712 US7341727B1 (en) | 1996-05-03 | 1996-05-03 | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| PCT/US1997/007679 WO1997041731A1 (en) | 1996-05-03 | 1997-04-28 | Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA68332C2 true UA68332C2 (en) | 2004-08-16 |
Family
ID=24577687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA98126370A UA68332C2 (en) | 1996-05-03 | 1997-04-28 | Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants) |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US7341727B1 (es) |
| EP (1) | EP0900025B1 (es) |
| JP (2) | JP4401437B2 (es) |
| CN (2) | CN1222618C (es) |
| AR (1) | AR006999A1 (es) |
| AT (1) | ATE244016T1 (es) |
| AU (1) | AU723528B2 (es) |
| BG (1) | BG64832B1 (es) |
| BR (1) | BR9711090A (es) |
| CA (1) | CA2253636C (es) |
| CZ (1) | CZ298034B6 (es) |
| DE (1) | DE69723254T2 (es) |
| EA (1) | EA002743B1 (es) |
| EE (1) | EE04684B1 (es) |
| ES (1) | ES2202624T3 (es) |
| GE (1) | GEP20022695B (es) |
| HK (2) | HK1021299A1 (es) |
| HU (1) | HU223004B1 (es) |
| NO (2) | NO324816B1 (es) |
| NZ (1) | NZ332896A (es) |
| PL (3) | PL189374B1 (es) |
| SK (1) | SK284812B6 (es) |
| TW (1) | TW541314B (es) |
| UA (1) | UA68332C2 (es) |
| WO (1) | WO1997041731A1 (es) |
| ZA (1) | ZA973809B (es) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440425B1 (en) * | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US6335018B1 (en) * | 1995-05-01 | 2002-01-01 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US7341727B1 (en) * | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| AUPO652897A0 (en) | 1997-04-30 | 1997-05-29 | University Of Melbourne, The | Synthetic peptide constructs for the diagnosis and treatment of periodontitis |
| GB9714276D0 (en) | 1997-07-08 | 1997-09-10 | Univ Dundee | Peptides and related compounds |
| US8129500B2 (en) * | 1997-12-10 | 2012-03-06 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
| GB9808720D0 (en) * | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| GB9810084D0 (en) | 1998-05-11 | 1998-07-08 | Cortecs Uk Ltd | Proteins |
| GB9810193D0 (en) * | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
| AU4260099A (en) * | 1998-05-12 | 1999-11-29 | Smithkline Beecham Biologicals (Sa) | Compounds from moraxella catarrhalis |
| GB9810285D0 (en) * | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| US6541616B1 (en) | 1998-10-01 | 2003-04-01 | Antex Biologics Inc. | Moraxella catarrhalis protein, gene sequence and uses thereof |
| HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
| US6673910B1 (en) | 1999-04-08 | 2004-01-06 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics |
| DE60039108D1 (de) * | 1999-05-24 | 2008-07-17 | Glaxosmithkline Biolog Sa | Neue verbindungen aus moraxella catarrhalis |
| GB9915031D0 (en) * | 1999-06-25 | 1999-08-25 | Smithkline Beecham Biolog | Novel compounds |
| ES2290056T3 (es) * | 1999-09-14 | 2008-02-16 | Glaxosmithkline Biologicals S.A. | Polipeptidos de moraxella (branhamella) catarrhalis. |
| GB9921691D0 (en) * | 1999-09-14 | 1999-11-17 | Smithkline Beecham Sa | Novel compounds |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| SE0102410D0 (sv) * | 2001-07-04 | 2001-07-04 | Arne Forsgren | Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis |
| JP4740738B2 (ja) | 2002-08-02 | 2011-08-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
| CN100357318C (zh) * | 2005-10-11 | 2007-12-26 | 中山大学 | 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用 |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP3020411A1 (en) | 2005-12-22 | 2016-05-18 | GlaxoSmithKline Biologicals s.a. | Vaccine |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| UA92782C2 (ru) | 2006-01-17 | 2010-12-10 | Арне Форсгрен | Новый поверхностный белок haemophilus influenzae (белок е; ре) |
| JP2009544279A (ja) * | 2006-06-27 | 2009-12-17 | オーラル ヘルス オーストラリア ピーティーワイ リミテッド | 歯周病の予防に有用なポルフィロモナス・ジンジバリスポリペプチド |
| PT2167121E (pt) | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae |
| EP2175851B1 (en) * | 2007-07-12 | 2013-05-15 | Oral Health Australia Pty Ltd | Biofilm treatment |
| US20100297179A1 (en) * | 2007-07-12 | 2010-11-25 | Stuart Geoffrey Dashper | Immunology Treatment for Biofilms |
| US8642046B2 (en) * | 2007-10-09 | 2014-02-04 | Tufts University | Cholera vaccines |
| TWI473626B (zh) | 2008-08-29 | 2015-02-21 | Oral Health Australia Pty Ltd | 牙齦紫單胞菌（ｐ.ｇｉｎｇｉｖａｌｉｓ）感染之預防、治療及診斷技術 |
| US8140041B2 (en) * | 2009-08-27 | 2012-03-20 | Mediatek Inc. | Tunable capacitive device with linearization technique employed therein |
| ES2366735B1 (es) * | 2009-10-08 | 2012-09-13 | Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla | Vacuna frente a acinetobacter baumannii. |
| US9855735B2 (en) | 2009-11-23 | 2018-01-02 | Cyvek, Inc. | Portable microfluidic assay devices and methods of manufacture and use |
| US10022696B2 (en) | 2009-11-23 | 2018-07-17 | Cyvek, Inc. | Microfluidic assay systems employing micro-particles and methods of manufacture |
| JP5701894B2 (ja) | 2009-11-23 | 2015-04-15 | サイヴェク・インコーポレイテッド | アッセイを行う方法及び装置 |
| US9500645B2 (en) | 2009-11-23 | 2016-11-22 | Cyvek, Inc. | Micro-tube particles for microfluidic assays and methods of manufacture |
| US10065403B2 (en) | 2009-11-23 | 2018-09-04 | Cyvek, Inc. | Microfluidic assay assemblies and methods of manufacture |
| WO2013134742A2 (en) | 2012-03-08 | 2013-09-12 | Cyvek, Inc | Micro-tube particles for microfluidic assays and methods of manufacture |
| US9700889B2 (en) | 2009-11-23 | 2017-07-11 | Cyvek, Inc. | Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results |
| US9759718B2 (en) | 2009-11-23 | 2017-09-12 | Cyvek, Inc. | PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| BR112012022688A2 (pt) | 2010-03-10 | 2018-05-22 | Glaxosmithkline Biologicals Sa | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
| WO2011130434A2 (en) | 2010-04-13 | 2011-10-20 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
| US8501197B2 (en) | 2010-04-30 | 2013-08-06 | The Research Foundation for The State of New York | Compositions and methods for stimulating immune response against Moraxella catarrhalis |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| CN106552682B (zh) | 2011-03-22 | 2020-06-19 | 西维克公司 | 微流体装置以及制造方法和用途 |
| RU2481401C2 (ru) * | 2011-07-15 | 2013-05-10 | Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) | СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS |
| US11210432B2 (en) * | 2013-08-20 | 2021-12-28 | Janus Technologies, Inc. | Method and apparatus for selectively snooping and capturing data for secure computer interfaces |
| US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| US10228367B2 (en) | 2015-12-01 | 2019-03-12 | ProteinSimple | Segmented multi-use automated assay cartridge |
| WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| US12016919B2 (en) | 2017-05-30 | 2024-06-25 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| CA3083078A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| AU2019256383A1 (en) | 2018-04-17 | 2020-11-26 | Celldex Therapeutics, Inc. | Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs |
| US20210283238A1 (en) | 2018-08-07 | 2021-09-16 | Glaxosmithkline Biologicals Sa | Novel processes and vaccines |
| CN111157735B (zh) * | 2018-11-07 | 2023-02-07 | 广州万孚生物技术股份有限公司 | 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用 |
| EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| US20220016168A1 (en) | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| JP2022535091A (ja) | 2019-06-05 | 2022-08-04 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
| CN111778226B (zh) * | 2020-07-21 | 2022-04-05 | 东北师范大学 | 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用 |
| CA3214853A1 (en) | 2021-04-09 | 2022-10-13 | Celidex Therapeutics, Inc. | Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof |
| WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675176A (en) * | 1983-12-12 | 1987-06-23 | Norden Laboratories | Moraxella bovis protease vaccine |
| US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| US5552146A (en) * | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
| US5607846A (en) | 1994-05-17 | 1997-03-04 | Research Foundation Of State University Of New York | Vaccine for moraxella catarrhalis |
| US6335018B1 (en) * | 1995-05-01 | 2002-01-01 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US6440425B1 (en) * | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US7341727B1 (en) * | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| GB9809683D0 (en) | 1998-05-06 | 1998-07-01 | Smithkline Beecham Biolog | Novel compounds |
| GB9812163D0 (en) | 1998-06-05 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
-
1996
- 1996-05-03 US US08/642,712 patent/US7341727B1/en not_active Expired - Fee Related
-
1997
- 1997-04-28 UA UA98126370A patent/UA68332C2/uk unknown
- 1997-04-28 NZ NZ332896A patent/NZ332896A/en not_active IP Right Cessation
- 1997-04-28 EP EP97926409A patent/EP0900025B1/en not_active Expired - Lifetime
- 1997-04-28 PL PL97366359A patent/PL189374B1/pl not_active IP Right Cessation
- 1997-04-28 GE GEAP19974595A patent/GEP20022695B/en unknown
- 1997-04-28 AU AU31180/97A patent/AU723528B2/en not_active Ceased
- 1997-04-28 CN CNB971959900A patent/CN1222618C/zh not_active Expired - Fee Related
- 1997-04-28 CN CNB2005100924509A patent/CN100415871C/zh not_active Expired - Fee Related
- 1997-04-28 CZ CZ0352498A patent/CZ298034B6/cs not_active IP Right Cessation
- 1997-04-28 CA CA002253636A patent/CA2253636C/en not_active Expired - Fee Related
- 1997-04-28 BR BR9711090A patent/BR9711090A/pt not_active Application Discontinuation
- 1997-04-28 EA EA199800973A patent/EA002743B1/ru not_active IP Right Cessation
- 1997-04-28 HU HU9902695A patent/HU223004B1/hu not_active IP Right Cessation
- 1997-04-28 DE DE69723254T patent/DE69723254T2/de not_active Expired - Lifetime
- 1997-04-28 EE EE9800373A patent/EE04684B1/xx not_active IP Right Cessation
- 1997-04-28 PL PL97330935A patent/PL189995B1/pl not_active IP Right Cessation
- 1997-04-28 PL PL97366360A patent/PL189375B1/pl not_active IP Right Cessation
- 1997-04-28 SK SK1509-98A patent/SK284812B6/sk not_active IP Right Cessation
- 1997-04-28 WO PCT/US1997/007679 patent/WO1997041731A1/en active IP Right Grant
- 1997-04-28 ES ES97926409T patent/ES2202624T3/es not_active Expired - Lifetime
- 1997-04-28 JP JP54015697A patent/JP4401437B2/ja not_active Expired - Fee Related
- 1997-04-28 AT AT97926409T patent/ATE244016T1/de not_active IP Right Cessation
- 1997-05-01 TW TW086105809A patent/TW541314B/zh not_active IP Right Cessation
- 1997-05-02 ZA ZA9703809A patent/ZA973809B/xx unknown
- 1997-05-05 AR ARP970101850A patent/AR006999A1/es active IP Right Grant
- 1997-11-12 US US08/968,685 patent/US6214981B1/en not_active Expired - Fee Related
-
1998
- 1998-11-02 NO NO19985113A patent/NO324816B1/no not_active IP Right Cessation
- 1998-12-02 BG BG102983A patent/BG64832B1/bg unknown
-
2000
- 2000-01-18 HK HK00100316A patent/HK1021299A1/xx not_active IP Right Cessation
-
2001
- 2001-03-20 US US09/813,214 patent/US7128910B2/en not_active Expired - Fee Related
-
2006
- 2006-08-18 NO NO20063711A patent/NO20063711L/no not_active Application Discontinuation
- 2006-10-16 US US11/580,854 patent/US7576179B2/en not_active Expired - Fee Related
-
2007
- 2007-01-12 HK HK07100467.7A patent/HK1095358A1/xx not_active IP Right Cessation
- 2007-10-26 US US11/925,586 patent/US20080145916A1/en not_active Abandoned
-
2008
- 2008-01-10 JP JP2008003407A patent/JP2008161194A/ja active Pending
-
2009
- 2009-08-14 US US12/541,701 patent/US7914795B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA68332C2 (en) | Moraxeila catarrhalis outer membrane protein-106 (omp106) polypeptide, peptide fragment and encoding nucleotide sequences, antibodies binding omp106 polypeptide, vaccine and antigenic composition (variants), methods of inducing immune responses to m. catarrhalis in animals (variants), method for treatment and prevention of m. catarrhalis infection (variants) | |
| KR100361562B1 (ko) | 프로테이나제k에대해내성을갖는네이쎄리아메닝기티디스의표면단백질 | |
| EA007409B1 (ru) | Антигенные полипептиды стрептококков, способы их получения и применения | |
| US10603373B2 (en) | Targets of Acinetobacter baumannii | |
| AU7643387A (en) | A neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin | |
| RU2252224C2 (ru) | Пептид со свойствами антигена neisseria meningitidis, кодирующий его полинуклеотид, вакцина для лечения или предотвращения заболеваний или состояний, вызванных neisseria meningitidis, (варианты), антитело, связывающееся с указанным пептидом | |
| EP0592470A1 (en) | Pseudomonas exoenzyme s peptide composition and methods for their production | |
| US7311917B2 (en) | Moraxella catarrhalis protein, gene sequence and uses thereof | |
| KR100366482B1 (ko) | 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법 | |
| US20090246228A1 (en) | Moraxella catarrhalis Proteins | |
| El-Adhami et al. | Characterization of the gene encoding a 26-kilodalton protein (OMP26) from nontypeable Haemophilus influenzae and immune responses to the recombinant protein | |
| CA2520386A1 (en) | Nontypeable haemophilus influenzae virulence factors | |
| US20050032103A1 (en) | Nucleic acids and polypeptides specific for pathogenic strains of the Neisseria genus | |
| US6218147B1 (en) | Haemophilus adhesin protein | |
| KR100500000B1 (ko) | 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도 | |
| CA2182046A1 (en) | Haemophilus adhesin protein | |
| WO2004104044A1 (ja) | 抗体の製造方法 |